Wrclinsearch LLC

1. Pfizer Inc. $1,032,680 90 payments
2. Takeda Pharmaceuticals U.S.A., Inc. $55,439 9 payments
3. Shire North American Group Inc $600 1 payment
4. GlaxoSmithKline, LLC. $406 1 payment

1. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $762,358 35 payments
2. A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $122,401 27 payments
3. A Phase 2A Randomized Double Blind Sponsoropen Placebo Controlled Parallel Group Study to Assess the Pharmacodynamics Safety and Tolerability of Pf05221304 and Pf06865571 Coadministered for 6 Weeks in Adults With Nonalcoholic Fatty Liver Disease Nafld $86,725 10 payments
4. A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis $55,439 9 payments
5. An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $28,950 5 payments
6. An Interventional Efficacy and Safety Phase 3 Doubleblind 2Arm Study to Investigate Orally Administered Ibuzatrelvir Compared With Placebo in Nonhospitalized Symptomatic Adult and Adolescent Participants With Covid19 Who Are at High Risk of Progressing to Severe Illness $14,349 2 payments
7. A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $11,640 3 payments
8. A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $6,052 3 payments
9. A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of Shp626, An Apical Sodium-Dependent Bile Acid Transporter Inhibitor Asbti in Adults With Nonalcoholic Steatohepatitis Nash $600 1 payment
10. A Phase 1/2, Randomized, Observer-Blinded, Multi-Country Study to Eval $406 1 payment

1. Other $55,439 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.